● Recruiting

Clofarabine Therapy in Locally Advanced or Metastatic Urothelial Carcinoma

Condition: Advanced Urothelial Carcinoma · Metastatic Urothelial Cancer · Sponsor: Ekaterina Laukhtina

PhasePhase 1/Phase 2

Planned participants50

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This phase 1/2 study will evaluate the maximum tolerated dose, efficacy, and safety of clofarabine in patients with advanced or metastatic urothelial cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Ekaterina Laukhtina Dr., Medical Doctor · +43 (0)1 40400-26315 · ekaterina.laukhtina@meduniwien.ac.at

Always discuss trial participation with your own doctor first.

Locations (1)

Department of Urology, Medical University of Vienna

Vienna, Austria

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07034053